Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $44.25.

Several equities research analysts recently weighed in on STOK shares. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a report on Friday, August 21st. They set an “overweight” rating and a $40.00 target price for the company. Canaccord Genuity Group decreased their price target on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Wedbush lifted their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. The Goldman Sachs Group reiterated a “buy” rating on shares of Stoke Therapeutics in a research report on Thursday, September 10th. Finally, Guggenheim reissued a “buy” rating and set a $60.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th.

Insider Buying and Selling

In related news, Director Edward M. Md Kaye sold 12,567 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the sale, the director directly owned 124,557 shares in the company, valued at $3,989,560.71. This represents a 9.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 7,176 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04. Following the sale, the insider directly owned 20,422 shares of the company’s stock, valued at $593,054.88. The trade was a 26.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 34,594 shares of company stock valued at $1,069,305 over the last three months. 9.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in Stoke Therapeutics during the 2nd quarter valued at approximately $192,307,000. Jupiter Topco LLC purchased a new stake in Stoke Therapeutics in the 2nd quarter worth approximately $59,358,000. Troluce Capital Advisors LLC bought a new stake in shares of Stoke Therapeutics in the 1st quarter worth approximately $21,255,000. Wellington Management Group LLP grew its position in shares of Stoke Therapeutics by 13.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock worth $115,152,000 after buying an additional 423,601 shares during the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in shares of Stoke Therapeutics in the 2nd quarter worth approximately $11,630,000.

Stoke Therapeutics Stock Up 7.2%

NASDAQ STOK opened at $26.61 on Friday. The company has a 50-day simple moving average of $28.37 and a two-hundred day simple moving average of $30.45. Stoke Therapeutics has a 12-month low of $20.32 and a 12-month high of $40.22. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -7.97 and a beta of 1.26.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Equities analysts expect that Stoke Therapeutics will post -3.52 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.